(Q33826230)

29 July 2017

1 reference

title

Indinavir: a review of its use in the management of HIV infection (English)

1 reference

29 July 2017

1 reference

Plosker GL

1

1 reference

PubMed ID

10651394

29 July 2017

Noble S

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

58

1 reference

29 July 2017

6

1 reference

29 July 2017

1165-1203

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199958060-00011

29 July 2017

0 references

cites work

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

FDA warns of potential protease-inhibitor link to hyperglycaemia

1 reference

12 December 2020

Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).

1 reference

12 December 2020

Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir

1 reference

12 December 2020

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

12 December 2020

Resistance to HIV protease inhibitors

1 reference

12 December 2020

Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors

1 reference

12 December 2020

Acute interstitial nephritis secondary to the administration of indinavir

1 reference

12 December 2020

Risk of new AIDS diseases in people on triple therapy

1 reference

12 December 2020

Therapeutic concentrations of indinavir in cerebrospinal fluid of HIV-1-infected patients

1 reference

12 December 2020

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Haemolytic anaemia associated with indinavir

1 reference

12 December 2020

Protease inhibitor-associated hyperinsulinaemia

1 reference

12 December 2020

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

1 reference

12 December 2020

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

1 reference

12 December 2020

Changes in renal function associated with indinavir

1 reference

12 December 2020

Ketoacidosis associated with protease inhibitor therapy

1 reference

12 December 2020

Indinavir and thrombocytopenia

1 reference

12 December 2020

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds.

1 reference

12 December 2020

Acute generalized exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor

1 reference

12 December 2020

Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir

1 reference

12 December 2020

Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy

1 reference

12 December 2020

Insulin resistance in HIV protease inhibitor-associated diabetes

1 reference

12 December 2020

Indinavir-induced renal failure

1 reference

12 December 2020

Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection

1 reference

12 December 2020

HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

The effect of protease inhibitors on weight and body composition in HIV-infected patients

1 reference

12 December 2020

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy

1 reference

12 December 2020

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

1 reference

12 December 2020

Protease inhibitors in antiviral therapy of paediatric HIV disease

1 reference

12 December 2020

Coronary artery disease occurring with protease inhibitor therapy

1 reference

12 December 2020

Indinavir nephropathy

1 reference

12 December 2020

Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.

1 reference

12 December 2020

Effect of indinavir on HIV-related wasting

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.

1 reference

12 December 2020

1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee

1 reference

12 December 2020

Urolithiasis associated with the protease inhibitor indinavir

1 reference

12 December 2020

Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus

1 reference

12 December 2020

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

Antiretroviral drugs and the central nervous system.

1 reference

12 December 2020

Protease inhibitor therapy in children with perinatally acquired HIV infection

1 reference

12 December 2020

[Benign symmetrical lipomatosis ("peripheral lipodystrophy") during antiretroviral therapy of HIV infection]

1 reference

12 December 2020

HIV-1 protease inhibitors. A review for clinicians

1 reference

12 December 2020

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

12 December 2020

Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy

1 reference

12 December 2020

Severe premature coronary artery disease with protease inhibitors

1 reference

12 December 2020

Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria.

1 reference

12 December 2020

Nephritic colic due to indinavir

1 reference

12 December 2020

In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans

1 reference

12 December 2020

Antiretroviral treatment in 1998.

1 reference

12 December 2020

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

12 December 2020

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

1 reference

12 December 2020

Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors

1 reference

12 December 2020

Images in clinical medicine. Indinavir crystalluria

1 reference

12 December 2020

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS

1 reference

12 December 2020

Renal atrophy associated with long-term treatment with indinavir

1 reference

12 December 2020

Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor.

1 reference

12 December 2020

Images in clinical medicine. Buffalo hump in a patient with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor

1 reference

12 December 2020

Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.

1 reference

12 December 2020

Indinavir crystal deposits associated with tubulointerstitial nephropathy

1 reference

12 December 2020

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Protease inhibitors for the treatment of human immunodeficiency virus infection

1 reference

12 December 2020

Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy

1 reference

12 December 2020

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.

1 reference

12 December 2020

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

1 reference

12 December 2020

Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine

1 reference

12 December 2020

"Buffalo hump" in HIV-1 infection

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Stevens-Johnson syndrome caused by indinavir

1 reference

12 December 2020

The HIV-1 protease as a therapeutic target for AIDS

1 reference

12 December 2020

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

1 reference

12 December 2020

Subtle occurrence of indinavir-induced acute renal insufficiency.

1 reference

12 December 2020

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

12 December 2020

Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy

1 reference

12 December 2020

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Management of indinavir associated nephrolithiasis

1 reference

12 December 2020

Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro

1 reference

12 December 2020

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

12 December 2020

Early lipodystrophy occurring during post-exposure prophylaxis

1 reference

12 December 2020

Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up

1 reference

12 December 2020

"Buffalo hump" in HIV-1 infection

1 reference

12 December 2020

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

12 December 2020

Single-dose pharmacokinetics of indinavir and the effect of food.

1 reference

12 December 2020

Indinavir nephrolithiasis in warm climates

1 reference

12 December 2020

On the issue of cross-resistance between protease inhibitors.

1 reference

12 December 2020

Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors.

1 reference

12 December 2020

Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients

1 reference

12 December 2020

Is the combination of hepatitis and indinavir potentially dangerous?

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Benign symmetric lipomatosis associated with protease inhibitors

1 reference

12 December 2020

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

12 December 2020

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

1 reference

12 December 2020

The AIDS epidemic--considerations for the 21st century

1 reference

12 December 2020

Impact of drug resistance mutations on virologic response to salvage therapy

1 reference

12 December 2020

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

12 December 2020

A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy

1 reference

12 December 2020

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

1 reference

12 December 2020

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Severe hepatitis in three AIDS patients treated with indinavir

1 reference

12 December 2020

Hemolytic jaundice related to ingestion of indinavir

1 reference

12 December 2020

Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function.

1 reference

12 December 2020

Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors

1 reference

12 December 2020

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

12 December 2020

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

12 December 2020

Neurological efficacy of stavudine, zidovudine, and lamivudine.

1 reference

12 December 2020

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

12 December 2020

Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor.

1 reference

12 December 2020

Protease inhibitor-associated hyperglycaemia

1 reference

12 December 2020

Persistent nephrolithiasis after discontinuation of indinavir therapy

1 reference

12 December 2020

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

12 December 2020

Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

1 reference

12 December 2020

Lipodystrophy in patients naive to HIV protease inhibitors

1 reference

12 December 2020

Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience

1 reference

12 December 2020

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

12 December 2020

Crystalluria and urinary tract abnormalities associated with indinavir

1 reference

12 December 2020

New-onset diabetes mellitus associated with use of protease inhibitor

1 reference

12 December 2020

1 reference

12 December 2020

Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment

1 reference

12 December 2020

Indinavir concentrations and antiviral effect

1 reference

12 December 2020

Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients

1 reference

12 December 2020

HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals

1 reference

12 December 2020

Crystalluria and urinary tract abnormalities associated with indinavir

1 reference

12 December 2020

Indinavir-induced nephropathy

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

Indinavir and interstitial nephritis

1 reference

12 December 2020

Vascular complications associated with use of HIV protease inhibitors

1 reference

12 December 2020

Fatal acute haemolysis in an AIDS patient treated with indinavir

1 reference

12 December 2020

Survival of HIV-infected patients with cytomegalovirus retinitis under highly active antiretroviral therapy. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine

1 reference

12 December 2020

Light microscopy of indinavir urinary crystals

1 reference

12 December 2020

Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.

1 reference

12 December 2020

Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir

1 reference

12 December 2020

Early recovery of CD4+ T lymphocytes in children on highly active antiretroviral therapy. Dutch study group for children with HIV infections.

1 reference

12 December 2020

"Buffalo humps" associated with protease inhibitors

1 reference

12 December 2020

Hyperlipidemia under treatment with proteinase inhibitors

1 reference

12 December 2020

Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis

1 reference

12 December 2020

Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation

1 reference

12 December 2020

Drug interactions of HIV protease inhibitors

1 reference

12 December 2020

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

12 December 2020

10.2165/00003495-199958060-00011

Identifiers

DOI

1 reference

PubMed ID

10651394

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

10651394